These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33252556)

  • 21. Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease.
    Jalali Y; Gojdicova A; Sturdik I; Toth J; Koller T; Huorka M; Jalali M; Payer J; Hlavaty T
    Bratisl Lek Listy; 2023; 124(7):485-492. PubMed ID: 37218475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
    Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
    Nanda KS; Cheifetz AS; Moss AC
    Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
    Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab.
    Yokoyama Y; Sawada K; Aoyama N; Yoshimura N; Sako M; Hirai F; Kashiwagi N; Suzuki Y
    J Crohns Colitis; 2020 Sep; 14(9):1264-1273. PubMed ID: 32166331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
    Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
    J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.
    Jagt JZ; Holleman KW; Benninga MA; Van Limbergen JE; de Boer NKH; de Meij TGJ
    J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):57-67. PubMed ID: 38291692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum infliximab concentrations in pediatric inflammatory bowel disease.
    Hämäläinen A; Sipponen T; Kolho KL
    Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
    Veisman I; Yablecovitch D; Kopylov U; Eliakim R; Ben-Horin S; Ungar B
    Isr Med Assoc J; 2021 Dec; 23(12):788-793. PubMed ID: 34954918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
    Dave MB; Dherai AJ; Desai DC; Keny BG; Shetty DN; Kulkarni S; Peddy K; Ashavaid TF
    Indian J Gastroenterol; 2020 Oct; 39(5):426-434. PubMed ID: 33118097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
    Hernández-Breijo B; Chaparro M; Cano-Martínez D; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Gisbert JP; Guijarro LG;
    Biochem Pharmacol; 2016 Dec; 122():33-41. PubMed ID: 27664854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
    Levesque BG; Greenberg GR; Zou G; Sandborn WJ; Singh S; Hauenstein S; Ohrmund L; Wong CJ; Stitt LW; Shackelton LM; King D; Lockton S; Ducharme J; Feagan BG
    Aliment Pharmacol Ther; 2014 May; 39(10):1126-35. PubMed ID: 24689499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Bar-Yoseph H; Levhar N; Selinger L; Manor U; Yavzori M; Picard O; Fudim E; Kopylov U; Eliakim R; Ben-Horin S; Chowers Y; Ungar B
    Aliment Pharmacol Ther; 2018 Jan; 47(2):212-218. PubMed ID: 29124774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
    Vande Casteele N; Khanna R; Levesque BG; Stitt L; Zou GY; Singh S; Lockton S; Hauenstein S; Ohrmund L; Greenberg GR; Rutgeerts PJ; Gils A; Sandborn WJ; Vermeire S; Feagan BG
    Gut; 2015 Oct; 64(10):1539-45. PubMed ID: 25336114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.